Protamine

Drug class: Antineoplastic Agents

Usage of Protamine

Heparin Overdosage

Treatment of severe heparin overdosage.

Do not use for minor bleeding during heparin therapy. (See Boxed Warning.) Heparin withdrawal usually corrects minor overdosage or bleeding within a few hours.

Heparin Neutralization during Extracorporeal Circulation

Neutralization of heparin administered during extracorporeal circulation† [off-label] in arterial and cardiac surgery or dialysis procedures.

Heparin Neutralization in Pregnant Women Near Delivery

Neutralization of anticoagulant effect of heparin to reduce risk of bleeding near delivery† [off-label] in pregnant women receiving heparin therapy who go into spontaneous labor.

Low Molecular Weight Heparin Overdosage

Has been used for treatment of low molecular weight (LMW) heparin (e.g., dalteparin, enoxaparin, tinzaparin [no longer commercially available in the US]) overdosage† [off-label]. However, neutralization of an LMW heparin is not complete even with multiple doses of protamine. (See Actions.)

Relate drugs

How to use Protamine

General

Heparin Overdosage

  • With severe heparin overdosage, discontinue heparin and administer protamine sulfate immediately. Blood transfusions may be required for massive blood loss.
  • Dose of protamine sulfate determined by dose of heparin received, route of administration, time elapsed since heparin was given, and blood coagulation studies. Generally, 1 mg of protamine sulfate will neutralize no less than 100 units of heparin sodium.
  • Blood heparin concentrations decrease rapidly after IV administration of heparin; dose of protamine sulfate required in the treatment of IV heparin overdosage also decreases rapidly as time elapses.
  • Monitor therapeutic response through coagulation studies (aPTT, activated coagulation time [ACT], heparin titration test with protamine, plasma thrombin time).
  • Additional doses of protamine sulfate may be required in patients with heparin rebound (e.g., as may occur during extracorporeal circulation† [off-label] in arterial and cardiac surgery or dialysis procedures) if indicated by coagulation studies. (See Effects on Hemostasis under Cautions.)

    • Low Molecular Weight Heparin Overdosage† [off-label]

  • Dose of protamine sulfate determined by dose of LMW heparin received, the time elapsed since the drug was given, and blood coagulation studies.
  • Following higher doses of protamine sulfate, aPTT may remain more prolonged than would be the case following treatment of heparin overdosage since anti-factor Xa activity is never completely neutralized. A maximum of about 60–75% or 60% of anti-factor Xa activity is neutralized with protamine sulfate administration for overdosage of dalteparin or enoxaparin, respectively.

    • Administration

    IV Administration

    For solution and drug compatibility information, see Compatibility under Stability.

    Administer by very slow IV injection. (See Sensitivity Reactions under Cautions.)

    Has been administered by continuous IV infusion†.

    Dilution

    May be administered without further dilution at a concentration of 10 mg/mL. However, if more dilute infusion solution is desired, further dilution in 5% dextrose or 0.9% sodium chloride injection recommended. Contains no preservatives; discard unused portion.

    Rate of Administration

    Administer by very slow IV injection over 10 minutes.

    Dosage

    Available as protamine sulfate; dosage expressed in terms of the salt.

    Adults

    Heparin Overdosage IV

    Severe bleeding occurring a few minutes after IV injection of heparin: 1 mg for every 100 units of heparin sodium administered.

    Severe bleeding occurring 30 minutes after IV injection of heparin: 0.5 mg for every 100 units of heparin sodium administered.

    Severe bleeding occurring ≥2 hours after IV injection of heparin: 0.25–0.375 mg for every 100 units of heparin sodium administered.

    Severe bleeding occurring after sub-Q injection of heparin: Some clinicians recommend 1–1.5 mg for every 100 units of heparin sodium; prolonged infusion may be required to neutralize sub-Q heparin dose. A loading dose of 25–50 mg by slow IV infusion suggested by some clinicians, with remainder of calculated dose administered by continuous IV infusion† over 8–16 hours or expected duration of absorption of heparin.

    Heparin Neutralization During Extracorporeal Circulation† IV

    1.5 mg for every 100 units of heparin sodium administered. Alternatively, determine dosage by using sequential ACT determinations and a dose-response curve which correlates results with amount of heparin remaining in body.

    Low Molecular Weight Heparin Overdosage† IV

    Severe bleeding within 8 hours of administration of an LMW heparin: 1 mg for every 100 anti-factor Xa units of LMW heparin (e.g., enoxaparin sodium, dalteparin sodium, tinzaparin sodium) administered (e.g., 1 mg of enoxaparin sodium has an anti-factor Xa activity of approximately 100 units). If aPTT measured 2–4 hours after first infusion of protamine sulfate remains prolonged or if bleeding continues, may administer a second dose of 0.5 mg protamine sulfate for every 100 anti-factor Xa units of LMW heparin administered.

    Severe bleeding >8 hours after administration of an LMW heparin: 0.5 mg for every 100 anti-factor Xa units of LMW heparin administered.

    Protamine sulfate administration may not be required if >12 hours has elapsed since administration of enoxaparin.

    Prescribing Limits

    Adults

    Heparin Overdosage IV

    Maximum 50 mg administered in any 10-minute period, unless larger dose clearly needed. (See Sensitivity Reactions under Cautions.)

    Warnings

    Contraindications

  • Known hypersensitivity to protamine sulfate.

    • Warnings/Precautions

    Warnings

    Effects on Hemostasis

    Heparin rebound (hyperheparinemia) with bleeding reported (e.g., after cardiac surgery, dialysis procedure).

    Heparin rebound usually occurs several hours after heparin has been adequately neutralized by protamine sulfate but has been reported 0.5–18 hours following cardiopulmonary bypass procedure†.

    Precise cause unknown; may result from release of heparin from protamine-heparin complex or from extravascular compartments. (See Metabolism under Pharmacokinetics.)

    Monitor patients closely following cardiac surgery; administer additional doses of protamine sulfate if indicated by coagulation studies.

    Sensitivity Reactions

    Severe hypotension and potentially fatal anaphylactoid reactions reported, particularly with large doses or too-rapid administration. Take particular care to avoid overdosage with protamine. (See Boxed Warning.)

    Patients at increased risk for development of antiprotamine antibodies and hypersensitivity reactions include infertile or vasectomized men, those with previous exposure to protamine-containing preparations (e.g., protamine-containing insulin, previous protamine sulfate therapy), or those with known hypersensitivity to fish.

    Severe reactions to IV protamine can occur in absence of local or systemic allergic reactions to sub-Q protamine-containing insulin. Fatal anaphylaxis reported in at least 1 patient with no prior history of allergies.

    Minimize these adverse effects by administering drug slowly. (See IV Administration under Dosage and Administration.) Administer only when medical facilities equipped to provide resuscitation and treat shock available. Patients at risk for protamine allergy can be pretreated with corticosteroids and antihistamines. (See Actions.)

    Specific Populations

    Pregnancy

    Category C.

    Lactation

    Not known whether protamine sulfate is distributed into milk. Use caution.

    Pediatric Use

    Safety and efficacy not established in children.

    Common Adverse Effects

    Decreased BP or hypotension, bradycardia, skin reactions (e.g., flushing, feeling of warmth, urticaria, edema), dyspnea, nausea, vomiting, lassitude, back pain.

    What other drugs will affect Protamine

    Specific Drugs

    Drug

    Interaction

    Heparin

    Neutralization of anticoagulant activity of heparin

    Insulin

    Prolongs absorption of insulin

    LMW heparins

    Incomplete neutralization of anticoagulant activity of LMW heparin

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords